May 19, 2016
May 2013, Vol 4 No 3 Safety of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Safety of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
This is the third article in a 4-part series on bendamustine. While the previous article discussed the efficacy of bendamustine for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in the registration studies cited in the US product labeling, this article discusses its safety.1 The next article in [ Read More ]
UncategorizedToxicity of Bendamustine Therapy
Bendamustine is an active chemotherapy agent approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients with non-Hodgkin lymphoma (NHL). While bendamustine has been reported to be very effective in treating these malignancies, its tolerable toxicity profile has made it [ Read More ]
UncategorizedSafety of Bendamustine in Treatment of CLL and NHL
Chronic Lymphocytic Leukemia Bendamustine is approved for single-agent use in chronic lymphocytic leukemia (CLL) based on the result from a phase 3 trial comparing bendamustine and chlorambucil.1 Progression-free survival was 18 months in the bendamustine group versus 6 months in the chlorambucil group. Bendamustine 100 mg/m2 was administered on days [ Read More ]
UncategorizedSafety of Bendamustine in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
The previous articles have outlined the clinical outcomes of clinical trials evaluating bendamustine in chronic lymphocytic leukemia (CLL) and non-HodgÂkin lymphoma (NHL). The third in the series of articles discusses the short-term toxicities of bendamustine from these clinical trials. Patients with CLL are always a challenge to treat due to [ Read More ]
Uncategorized